SNY logo

SANOFI-ADR

SNYNASDAQ
πŸ† #152 by market capEarnings Oct 30US Equity
$40.44β–Ό $0.73 (βˆ’1.81%)
Live
πŸ””
Track SNY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.8%
7dβ–Ό 4.7%
14dβ–Ό 4.6%
30dβ–Ό 9.8%
ytdβ–Ό 16.6%
1yβ–Ό 11.4%
🏦Market Cap
$97.09B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+5.5%
Slowing
πŸ“ŠGross Margin
72.8%
High
πŸ’΅FCF Margin
33.7%
Strong
βš–οΈP/S Ratio
1.8x
Cheap
Otter Score
52
Weak

Trading Snapshot

Day Range
$39.86 – $40.66
52-Week Range
$40.66 – $52.68
Volume
$3.84B
Avg Volume
$2.60B
Shares Outstanding
2.40B
Next Earnings
Nov 27, 2026

Fundamentals Snapshot

Annual Revenue
$46.72B
Last Q Revenue
$12.30B
P/E Ratio
22.0
P/S Ratio
1.8x
EPS (TTM)
$1.65
Dividend Yield
11.61%
Dilution (1yr)
βˆ’2.6%

Why Investors Own SNY

  • βœ“High-growth profile β€” revenue up -0.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 28% gross margin and 14% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SNY logo

SANOFI-ADR

SNY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$46.7Bβ–² +5.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.1%β–² +2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$9.6Bβ–² +32.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10.1Bβ–² +72.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.44Bβ–Ό βˆ’2.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$12.7Bβ–Ό βˆ’$2.2B YoY
StockOtter Β· stockotter.space

About SANOFI-ADR

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
52/100

Analyst Ratings

β“˜
Consensus
Buy
30 analysts
Strong Buy7
Buy10
Hold12
Sell1
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

πŸš€
Zacks Investment ResearchΒ·7h ago

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Zacks Investment ResearchΒ·4d ago

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Defense WorldΒ·6d ago

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

Sanofi (NASDAQ: SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research

Seeking AlphaΒ·7d ago

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MarketBeatΒ·9d ago

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss

Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company's executive vice

Seeking AlphaΒ·13d ago

Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive

Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting the 2026 outlook. Newer launches are scaling faster, giving Sanofi a clearer path toward a more diversified revenue bas